Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins
Author:
Open Access
Abstract
As antibody–drug conjugates have become a very important modality for cancer therapy, many site-specific conjugation approaches have been developed for generating homogenous molecules. The selective antibody coupling is achieved through antibody engineering by introducing specific amino acid or unnatural amino acid residues, peptides, and glycans. In addition to the use of synthetic cytotoxins, these novel methods have been applied for the conjugation of other payloads, including non-cytotoxic compounds, proteins/peptides, glycans, lipids, and nucleic acids. The non-cytotoxic compounds include polyethylene glycol, antibiotics, protein degraders (PROTAC and LYTAC), immunomodulating agents, enzyme inhibitors and protein ligands. Different small proteins or peptides have been selectively conjugated through unnatural amino acid using click chemistry, engineered C-terminal formylglycine for oxime or click chemistry, or specific ligation or transpeptidation with or without enzymes. Although the antibody protamine peptide fusions have been extensively used for siRNA coupling during early studies, direct conjugations through engineered cysteine or lysine residues have been demonstrated later. These site-specific antibody conjugates containing these payloads other than cytotoxic compounds can be used in proof-of-concept studies and in developing new therapeutics for unmet medical needs.Keywords
Funding Information
- Sanofi
This publication has 121 references indexed in Scilit:
- Antibody-Linked Spherical Nucleic Acids for Cellular TargetingJournal of the American Chemical Society, 2012
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acidsProceedings of the National Academy of Sciences of the United States of America, 2012
- Site-specific chemical protein conjugation using genetically encoded aldehyde tagsNature Protocols, 2012
- Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesinProceedings of the National Academy of Sciences, 2012
- Chemically Programmed Antibodies Targeting Multiple Alpha(v) Integrins and Their Effects on Tumor-Related Functions in VitroBioconjugate Chemistry, 2011
- Design and Application of Antibody Cysteine VariantsBioconjugate Chemistry, 2010
- Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tagProceedings of the National Academy of Sciences, 2009
- T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized MiceCell, 2008
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNature Biotechnology, 2008
- Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1Proceedings of the National Academy of Sciences, 2007